Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma

NCT06614855 is registered in ClinicalTrials.gov with James Markert, MD as lead sponsor.

NCT NCT06614855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06614855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma
Lead sponsor
James Markert, MD
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 2, 2025
Completion date
January 1, 2028
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma, astrocytoma, grade iii, astrocytoma, grade iv, glioblastoma, glioblastoma (gbm), gliosarcoma of brain, gliosarcoma, adult